价格

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

No. 288, Nanjing Road, Heping District, Tianjin, 中国

别名:

institute of hematology & blood diseases hospital, china

概览

试验阶段分布

阶段

试验数

占比

2 期

147

37.8%

1 期

101

26.0%

不适用

16.4%

4 期

4.1%

3 期

3.1%

早期 1 期

1.8%

试验状态分布

进行中（未招募）

4.9%

Available

0.3%

已完成

10.3%

Enrolling By Invitation

1.3%

尚未招募

108

27.8%

招募中

188

48.3%

终止

3.1%

Unknown

2.1%

撤回

2.1%

相关临床试验

该机构主办的试验（389）

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

Available

expanded access

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

药物批准

暂无批准数据

资讯

暂无资讯文章

返回机构列表

Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（389）

A Clinical Study of CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies

An Open-label Study of GC012F in Rheumatoid Arthritis.

Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia

A Study of Elranatamab for Inhibitor Eradication in Patients With Hemophilia A

Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

CM336-SOC for Dynamically High-Risk Multiple Myeloma Study

A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease

药物批准

资讯